Navigation Links
Mannatech to Begin Selling Nutritional Supplements in South Africa

New operation to launch in second quarter of 2008

COPPELL, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Mannatech, Incorporated (Nasdaq: MTEX), a leading developer and provider of dietary supplements and skin care solutions, announced today it will begin selling products in South Africa during the second quarter of this year.

Among these products will be the company's Optimal Health System, which is comprised of Ambrotose -- a patented blend of mixed plant saccharides; AO -- a proprietary antioxidant; PLUS -- an herbal-amino acid; and PhytoMatrix -- the industry's first all-natural multivitamin with concentrated, plant-sourced minerals and standardized phytochemicals.

"We are excited to enter the market in South Africa, which was the first country to grant a patent for the technology related to the formulation of Mannatech's flagship product, Ambrotose," said Mannatech President and CEO Terry Persinger. "South Africa has a rich tradition of using nature's biodiversity to help address quality of life and optimal health. This tradition aligns well with Mannatech products and our emphasis on natural ingredients."

About Mannatech

Mannatech, Incorporated, is a global wellness solutions provider of innovative, high-quality, proprietary nutritional supplements, topical and skin care products, and weight management products sold through independent associates and members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, and Germany.

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Contact Information:

Gary Spinell, Vice President

Investor Relations


Corporate website:

SOURCE Mannatech, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mannatech Names New VP of Regulatory Affairs, Quality Assurance
2. Mannatech to Open Centralized-Management Office in Switzerland
3. Mannatech Hosts Australasian Convention
4. Mannatech Hosts Japan National Convention
5. Mannatech Launches Phase One of New Sales and Training Tools
6. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
7. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
8. Hondros College Expands School of Nursing to Columbus and Dayton; Students Can Begin LPN Education Almost Immediately
9. High blood pressure worsening in all states for women; begins to stagnate for men
10. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
11. A New Beginning for Medicare Beneficiaries in North Carolina
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology: